Comparing a new epinephrine injector to EpiPen in adults with allergies
Part of Immune system & allergy clinical trials.
This study tests a new epinephrine auto-injector (FMXIN002) compared to the standard EpiPen in people with a history of hay fever or seasonal allergies. The goal is to see if the new device works just as well and is safe in a controlled clinic setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old.
- You are a non-smoker.
- You have a positive skin allergy test on record (a small scratch test that showed you’re allergic).
- You have a history of hay fever, seasonal allergies, or allergic rhinitis (runny/itchy nose) in the last year.
- If you are a female, you are not pregnant, not breastfeeding, and you agree to use effective birth control (unless you’ve had surgery or are past menopause).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if inhaled epinephrine can safely treat moderate to severe allergic reactions (grade 2 or higher) that can happen during allergy skin tests, oral food or drug challenges, or allergy shots. It is for people who have had such reactions in the past or are at risk and are planning to undergo one of these procedures.
This early-phase trial tests a new medication, LCA-0061, in healthy people with high IgE levels (a sign of allergies). Part B specifically includes those with a peanut allergy. The study aims to see how safe the drug is and how the body processes it.
This study compares a new nasal spray (neffy) to a standard epinephrine shot for treating severe allergic reactions during food challenges or allergy immunotherapy. It aims to see if the spray works as well and is safe.
This study is testing a new medicine (FMXIN002) for people who are at risk of a severe allergic reaction to food. If you have a known food allergy and have had a moderate reaction during a food challenge, you may be able to join. The trial will check if the medicine helps prevent or reduce the severity of future reactions.
This study tests a new injection called MG-K10 for people with moderate-to-severe seasonal hay fever that isn't well controlled by standard treatments like nasal sprays or antihistamines. The goal is to see if it can reduce your allergy symptoms over the pollen season.
This trial tests a new injection called GR1802 for people with seasonal allergic rhinitis (hay fever) that isn't well controlled by standard treatments. It aims to see if this medicine can help reduce symptoms during pollen season.
Hear when a new Anaphylaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.